Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials.
Ajay K SinghFinnian R Mc CauslandBrian L ClaggettChristoph WannerAndrzej WiecekMichael B AtkinsKevin CarrollVlado PerkovicJohn J V McMurrayJanet Turk WittesSteven SnapinnAllison BlackorbyAmy MeadowcroftTara BarkerTara DiMinoStephen MallettAlexander R CobitzScott D SolomonPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)
Prespecified on-treatment analyses for cancer-related AEs appeared to result in biased risk estimates in ASCEND-ND by preferentially under-counting events from patients assigned to darbepoetin. Analyses accounting for longer darbepoetin dosing intervals, or extending follow-up, resulted in attenuation of effect estimates towards neutrality, similar to ASCEND-D, where ESA comparator dosing intervals are closer to daprodustat.